A Phase I/II Trial to Evaluate the Safety and Tolerability of Alectinib and Bevacizumab in Patients With Advanced, ALK-Positive, Non-Small Cell Lung Cancer
Phase of Trial: Phase I/II
Latest Information Update: 19 Apr 2017
At a glance
- Drugs Alectinib (Primary) ; Bevacizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 19 Apr 2017 Last checked against ClinicalTrials.gov record.
- 16 Feb 2016 Status changed from not yet recruiting to recruiting, as reported by ClinicalTrials.gov.
- 18 Aug 2015 New trial record